Cargando…

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer

BACKGROUND: Despite the advent of improved therapeutic options for advanced prostate cancer, the durability of clinical benefits is limited due to inevitable development of resistance. By constitutively sustaining androgen receptor (AR) signaling, expression of ligand-binding domain truncated AR var...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Chiu-Lien, Liu, Hao-Hsuan, Fu, Chih-Wei, Yeh, Hsun-Hao, Hu, Tsan-Lin, Kuo, Zong-Keng, Lin, Yu-Chin, Jhang, Mei-Ru, Hwang, Chrong-Shiong, Hsu, Hung-Chih, Kung, Hsing-Jien, Wang, Ling-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011747/ https://www.ncbi.nlm.nih.gov/pubmed/36893587 http://dx.doi.org/10.1016/j.ebiom.2023.104500

Ejemplares similares

The clinical advances of proteolysis targeting chimeras in oncology
por: Xie, Hao, et al.
Publicado: (2021)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Shining a Light on Proteolysis Targeting Chimeras
por: Teichmann, Ellen, et al.
Publicado: (2019)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Proteolysis-targeting chimeras and their implications in breast cancer
por: Tecalco-Cruz, Angeles C., et al.
Publicado: (2021)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Assays and technologies for developing proteolysis targeting chimera degraders
por: Liu, Xingui, et al.
Publicado: (2020)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
por: Lebraud, Honorine, et al.
Publicado: (2016)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras
por: Zhao, Chunlong, et al.
Publicado: (2022)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Computer aided drug design in the development of proteolysis targeting chimeras
por: Tunjic, Tin M., et al.
Publicado: (2023)

Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
por: Yamanaka, Satoshi, et al.
Publicado: (2023)

Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism
por: Shih, Jing-Wen, et al.
Publicado: (2015)

Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
por: Kim, Kidae, et al.
Publicado: (2019)

Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
por: Zeng, Shenxin, et al.
Publicado: (2021)

Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
por: Lospinoso Severini, Ludovica, et al.
Publicado: (2022)

Emerging Strategies in Proteolysis-Targeting Chimeras (PROTACs): Highlights from 2022
por: Tamatam, Rekha, et al.
Publicado: (2023)

Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras
por: Wen, Tianzhi, et al.
Publicado: (2023)

Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
por: Ma, Ke, et al.
Publicado: (2021)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
por: Tashima, Toshihiko
Publicado: (2023)

Crizotinib‐based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation
por: Chen, Jin‐Jiao, et al.
Publicado: (2023)

Hypoxia deactivates epigenetic feedbacks via enzyme-derived clicking proteolysis-targeting chimeras
por: Do, Thang Cong, et al.
Publicado: (2022)

Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)

Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer
por: Wu, Meng-Jen, et al.
Publicado: (2021)

Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer
por: Liu, Jai-Shin, et al.
Publicado: (2022)

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
por: Goracci, Laura, et al.
Publicado: (2020)

A Mechanistic Pharmacodynamic Modeling Framework for the Assessment and Optimization of Proteolysis Targeting Chimeras (PROTACs)
por: Haid, Robin Thomas Ulrich, et al.
Publicado: (2023)

Comprehensive Transcriptomic Analysis of Novel Class I HDAC Proteolysis Targeting Chimeras (PROTACs)
por: Baker, India M., et al.
Publicado: (2022)

Proteolysis-targeting chimera against BCL-X(L) destroys tumor-infiltrating regulatory T cells
por: Kolb, Ryan, et al.
Publicado: (2021)

Degradation of neurodegenerative disease-associated TDP-43 aggregates and oligomers via a proteolysis-targeting chimera
por: Tseng, Yu-Ling, et al.
Publicado: (2023)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers
por: Chen, Chia-Lin, et al.
Publicado: (2021)

The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2)
por: Konstantinidou, Markella, et al.
Publicado: (2020)

Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
por: Salerno, Alessandra, et al.
Publicado: (2022)

MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment
por: Vicente, André T. S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_461qnqk8jdp4sp2eh1oa86ha9q